Advisor Group Holdings, Inc. Calliditas Therapeutics Ab Transaction History

Advisor Group Holdings, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	SELL	$17.65 - $41.41 $14,984 - $35,157	-849 Reduced 76.9%	255 $9,000
Q1 2024 May 10, 2024	SELL	$20.04 - $25.66 $1,362 - $1,744	-68 Reduced 5.8%	1,104 $23,000
Q4 2023 Feb 12, 2024	BUY	$15.79 - $28.99 $78 - $144	5 Added 0.43%	1,172 $30,000
Q2 2023 Aug 10, 2023	BUY	$15.7 - $25.61 $15,747 - $25,686	1,003 Added 611.59%	1,167 $18,000
Q2 2022 Aug 10, 2022	BUY	$12.85 - $20.36 $12 - $20	1 Added 0.61%	164 $3,000
Q3 2021 Nov 05, 2021	BUY	$21.03 - $33.19 $1,072 - $1,692	51 Added 45.54%	163 $3,000
Q2 2021 Aug 02, 2021	BUY	$26.02 - $31.17 $2,914 - $3,491	112 New	112 $3,000

4.17K

Ticker CALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,624,800
Market Cap $1.06B
Description
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

Stay updated on Advisor Group Holdings, Inc. with notifications on news.